Age, Menopausal Status, and Lymph Node Involvement Among Variables Associated With Abemaciclib Discontinuation in High-Risk Early Breast Cancer
June 6th 2022
Higher treatment discontinuation rates with abemaciclib were associated with factors including age of 65 year or older, enrollment in either North America or Europe, an ECOG performance status of 1, postmenopausal status, 1 to 3 positive lymph nodes, and 4 or more preexisting comorbidities in patients with hormone receptor–positive, HER2-negative high-risk early breast cancer.